

2020 Webinar Series

MEMBERS PRICE: **FREE**NON-MEMBERS PRICE:
\$90 + 5% GST PER WEBINAR

FEBRUARY 19, 2020

9:00am PT/12:00pm ET

CME Credit Hours: 1.0

Bronchiolitis Obliterans Syndrome (BOS)

Jane Turner, MD (Juravinski Hospital, Hamilton, ON)

LEARNING OBJECTIVES:

- Review of Bronchoilitis Obliterans Syndrome (BOS): Pathology; Mechanisms;
 Clinical diagnosis and trajectory
- 2. Management of HSCT-BOS
- 3. Recent evidence review: Azithromycin and beyond

MARCH 25, 2020

9:00am PT/12:00pm ET

CME Credit Hours: 1.0

Cellular Therapy Product Manufacturing and Testing - Current Techniques

Mike Halpenny, MLT (Canadian Blood Services, Ottawa, ON)

LEARNING OBJECTIVES:

- 1. Provide an overview of current processing methods and testing techniques for cellular therapy products, including cord blood, HPC, Apheresis and bone marrow.
- 2. Introduction to novel or advanced cell products, including CAR-T, and the role of the minimal manipulation laboratory with these new products

APRIL 8, 2020

12:00pm PT/3:00pm ET

CME Credit Hours: 1.0

Assessment of Comorbidities for Hematopoietic Cell Transplants: Achievements and Controversies

Mahmoud Elsawy, MD, MSc (Dalhousie University, Halifax, NS)

LEARNING OBJECTIVES:

- 1. Describing the milestones of evolution of comorbidities research in HCT
- 2. Highlighting the relevance of comprehensive comorbidities assessment
- 3. Reviewing the utilization of HCT specific- comorbidity index (HCT-CI)
- 4. Assessing strengths and weaknesses of the HCT-CI with a focus on methodology for calculating the HCT-CI score
- 5. Thoughts for the future

This webinar is sponsored by an unrestricted education grant from:

teva | Oncology | Canada

MAY 27, 2020

12:00pm PT/3:00pm ET

CME Credit Hours: 1.0

Neurotoxicity Post CAR-T Cell Therapy

Bianca Santomasso, MD (Memorial Sloan Kettering Cancer Center, New York, NY)

LEARNING OBJECTIVES:

TBA

AUGUST 26, 2020

9:00am PT/12:00pm ET

CME Credit Hours: 1.0

TCR T Cells, WT-1 T Cells and HA-1 TCR T Cells

Elizabeth Krakow, MD & Aude Chapuis, MD (Fred Hutchinson Cancer Research Center, Seattle, WA)

LEARNING OBJECTIVES:

- 1. Describe how TCR T cell differ from CAR-T cells
- 2. Familiarize participants with strategies for finding TCR targets and high-affinity, highly specific TCRs and for manufacturing TCR T cells
- 3. Share clinical results of TCR T cell trials to prevent and treatment post-transplant leukemia/MDS relapse

SEPTEMBER 16, 2020

9:00am PT/12:00pm ET

CME Credit Hours: 1.0

Poverty Matters: How Income Impacts Allogeneic Stem Cell Transplant

Kristjan Paulson, MD (University of Manitoba, CancerCare Manitoa, Winnipeg, MB)

LEARNING OBJECTIVES:

TBA

OCTOBER 28, 2020

12:00pm PT/3:00pm ET

CME Credit Hours: 1.0

The Role of Autologous Stem Cell Transplant in Myeloma in 2020

Donna Reece, MD (Princess Margaret Hospital, Toronto, ON)

LEARNING OBJECTIVES:

- 1. To understand the role of ASCT in the era of newer anti-myeloma treatments, including immunotherapy.
- 2. To discuss the use of post-ASCT treatment, with a focus on options for maintenance therapy.
- 3. To review strategies for improving the outcome of ASCT in high-risk myeloma patients.

NOVEMBER 25, 2020

12:00pm PT/3:00pm ET

CME Credit Hours: 1.0

Engineered Immune Effector Cells for Hematologic Malignancies

Kevin Hay, MD, MSc, FRCPC (BC Cancer Agency, Vancouver, BC)

LEARNING OBJECTIVES:

TBA

CTTC HEAD OFFICE

Suite 301, 750 West Pender Street, Vancouver, BC, V6C 2T7 T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org

